Stock PHN PHARMANUTRA S.P.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Pharmanutra S.p.A.

Equities

PHN

IT0005274094

Real-time Borsa Italiana
Other stock markets
 07:22:16 2024-06-10 am EDT 		5-day change 1st Jan Change
47.5 EUR -1.25% Intraday chart for Pharmanutra S.p.A. -2.86% -15.78%
May. 31 Milan up tentatively; Leonardo and banks do well AN
May. 30 Mib pegs 34,300; banking segment well AN

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's high margin levels account for strong profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The firm trades with high earnings multiples: 26.87 times its 2024 earnings per share.
  • With an enterprise value anticipated at 4.03 times the sales for the current fiscal year, the company turns out to be overvalued.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
PHARMANUTRA S.P.A. Stock Pharmanutra S.p.A.
-15.78% 500M
C
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+45.82% 765B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.16% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.86% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.32% 299B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.87% 248B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-1.72% 219B
A+
NOVARTIS AG Stock Novartis AG
+11.09% 216B
B-
AMGEN INC. Stock Amgen Inc.
+5.90% 164B
C+
PFIZER, INC. Stock Pfizer, Inc.
-0.73% 162B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PHN Stock
  4. Ratings Pharmanutra S.p.A.